Table 2.

Tumor response to benmelstobart plus anlotinib and chemotherapy

	Patients (n = 50)
Best response
Complete response	5 (10)
Partial response	31 (62)
Stable disease	6 (12)
Progressive disease	1 (2)
Not evaluablea	7 (14)
Objective responseb	36 (72.0; 57.5–83.8)
Disease controlc	42 (84.0; 70.9–92.8)

Data were expressed as n (%) or n (%; 95% confidence interval)

^a Not evaluable indicates patients with unevaluable post-baseline assessment or no post-baseline assessment available for tumor response

^b Objective response=Complete response plus partial response

^c Disease control=Complete response, partial response, plus stable disease